View
213
Download
0
Category
Preview:
Citation preview
EPIDEMIOLOGY
Hypertension Epidemiology and Cost of Illness
Dis Manage Health Outcomes 1997 Mar; 1 (3): 135- 140 1173-8790/97/0003-o135/S00.oo/0
© Adis International Limited. All rights reseNed.
Helios Pardell,1,2,3 Pedro Armario,1,2 Raquel Hernandez1,2 and Ricard Tresserras2,3
1 Department of Internal Medicine, Unit of Hypertension and Cardiovascular Risk, Red Cross Hospital, Hospitalet de Llobregat, Barcelona, Spain
2 Division of Health Sciences, School of Medicine, University of Barcelona, Barcelona, Spain 3 Public Health Service, Ministry of Health and Social Security, Government of Catalonia,
Barcelona, Spain
Contents Summary ........... . .. . 1. The Impact of HypertenSion .. . 2. Questions in Hypertension Control . 3. The Cost of HypertenSion . . . . . . 4. How to Reduce the Burden of HypertenSion 5. Conclusions . . . . . . . . . . .' . . . . . . . .
135 135 137 137 138 139
Summary Hypertension is one of the most prevalent chronic conditions and a major risk factor for cardiovascular disease. Unfortunately community control of hypertension remains unsatisfactory although treatment and control seems to be easy. The cost of treating hypertension is very high. It accounted for $US23.7 billion in the US (1995) and $US 1660 million in Spain (1994). It can be estimated that hypertension represents 5.8% of total deaths and 1.4% of total disability-adjusted life years (DALYs) worldwide. Although it is important to increase the implementation of secondary prevention strategies, even increasing the direct costs, it is currently accepted that more comprehensive strategies specially focused on primary prevention are needed to reduce the social impact of the burden of hypertension.
There are 2 pivotal ideas that clearly show the relevance of arterial hypertension in both developed and developing countries. First, more than half of the US population will develop hypertension during their lifetime.[l] Secondly, several epidemiological studies have consistently identified an important and independent link between high blood pressure and various disorders, especially coronary heart disease, stroke, congestive heart failure and impaired renal functionPl
Considering the elevated economic cost of hypertension and its complications, it is easy to understand the interest in analysing the epidemiological and social consequences of this highly prevalent risk factor.
1. The Impact of HypertenSion
The relevance of arterial hypertension is supported firstly by its high prevalence in almost all
136
countries worldwide, and secondly by its condition as the main cardiovascular risk factor.
Indeed, the prevalence of hypertension is very much influenced by the type of population considered, the different blood pressure devices and techniques used, and especially by the selected blood pressure cut-off point. If the classical cut-off point (160/95mm Hg) is taken, between 8 and 18% of the population can be considered as having hypertensionP1
In some countries, e.g. Spain, the prevalence rate is slightly higher (around 20% in the population over 18 years))41 In several eastern European countries, higher prevalence rates (up to 30%) have been observed)51 Conversely, in some populations with primitive lifestyles, e.g. some communities of Latin America, Africa and Oceania, hypertension prevalence is much lowerP1
When the most recent cut -off point (140/90mm Hg) is used, the prevalence of hypertension increases and reaches levels over 30% in the adult population.[61
Hypertension prevalence increases with age and is more frequent in the US Black population and in women aged over 45 years. It appears that hypertension prevalence is inversely related to socioeconomic status. Finally, high blood pressure shows a 'tracking' phenomenon (i.e. people with higher levels of blood pressure at baseline remain in the upper levels for life) at individual and community levels that is especially important in childhood and adolescence. [71
20 years ago, the researchers of the Framingham study[81 - which is the most important prospective study in the field of cardiovascular diseases -pointed out that the most useful single factor for detecting persons at high risk of cardiovascular disease was blood pressure. This is because a large body of evidence indicates that it is the most potent precursor of cardiovascular disease, although it is not equally important for all of these diseases)81 More recently, Kannel[91 stated that approximately 35% of atherosclerotic cardiovascular events may be attributable to hypertension.
© Adis International limited. All rights reserved .
Pardell et al.
The most relevant complications of high blood pressure are congestive heart failure, stroke, renal insufficiency, coronary heart disease and peripheral artery disease. The associated relative risks are 2.0 for coronary heart disease, 3.8 for stroke and 4.0 for congestive heart failure)9,101
A crucial distinction between individual and community risks must be made. For individuals, the relative risk is only an expression of the risk of being exposed and assuming that the higher the blood pressure the higher the risk. Indeed, a diastolic blood pressure of 114mm Hg entails much more risk than one of 100mm Hg for a particular person. Conversely, at the community level the number of individuals exposed to the risk is more important than the blood pressure figures .
The population attributable risk is the proportion of disease that can be attributed to hypertension i.e. the proportion of disease that could be avoided if hypertension were under control. The hypertension population attributable risk for coronary heart disease has been estimated as 22.7 in men.[91 Thus, mild hypertension (diastolic blood pressure 90 to 104mm Hg) entails much more attributable risk than severe hypertension because most patients with this condition (about 75%) have only mild hypertension.
The increase of risk is associated with both systolic and diastolic blood pressure. Cardiovascular risk increases dramatically when hypertension coincides with other cardiovascular risk factors in the same individual. This is not rare in practice (around 20% of hypertensives are smokers or have hypercholesterolaemia).[111
In the Multiple Risk Factor Intervention Trial, the risk of those individuals in the higher quintile for blood pressure and blood cholesterol who were smokers was 20-fold more than that observed in nonsmokers in the lowest blood pressure and blood cholesterol quintiles. [121
The impact of hypertension at the community level is enormous, constituting one of the most relevant public health problems in many countries. In the context of the Global Burden of Disease Study, Murray and Lopez[ 131 have estimated that hyper-
Dis Manage Health Outcomes 1997 Mar; 1 (3)
Hypertension: Epidemiology and Cost of Illness 137
Table I. The global burden 01 disease and injury attributable to selected risk factors in 1990 (reproduced from Murray et al .,1131 with permission)
Risk factor Deaths (x1oJ) Total deaths (%) DALYs (x106) Total DALYs
Malnutrition 5881 11.7 219.6 15.6
Poor water supply, sanitation and hygiene 2668
Unsafe sex 1095
Tobacco use 3038 Alcohol use n4 Occupation 1129
Hypertension 2918
Physical inactivity 1991
Illicit drugs use 100
Air pollution 568
Abbreviation: DALY = disability-adjusted life year.
tension is responsible for about 2918000 annual deaths worldwide, which equates to 5.8% of total deaths (table 1).[13)
2. Questions in Hypertension Control
The situation reported in section 1 could still be more worrying because in many countries less than 20% of people with hypertension have a blood pressure below 160/95mm Hg.ll4) Also, even worse, if we adopt the most recent and restrictive criteria of hypertension control (blood pressure < 140/90mm Hg) that proportion is substantially lower.
Surprisingly, although hypertension is a condition which is easy to diagnose, it often remains undetected. Also, although it may be simple to treat, this condition very often remains untreated. Despite the availability of nonpharmacological measures and potent medications, treatment is too often ineffective in practice (Strasser's triple paradOX).[15)
During recent years, hypertension control in the community has been widely analysed. At the World Conference on Hypertension Control held in Ottawa, Canada, in 1995, the most relevant problems in achieving significant hypertension control levels in the community were deeply analysed.l l6) According to the opinions of the experts, the more important barriers to reaching optimal community control levels are economic and cultural factors and those arising from the chronic condition ofhy-
© Adis International Limited. All rights reserved.
5.3 93.4 6.8
2.2 48.7 3.5
6.0 36.2 2.6
1.5 47.7 3.5
2.2 37.9 2.7
5.8 19.1 1.4
3.9 13.7 1.0
0.2 8.5 0.6
1.1 7.3 0.5
pertension.£l7-19) This point is especially important as approximately 40 to 50% of treated patients with hypertension do not adequately comply with the physicians' prescriptions(20) and, for several reasons closely related to the management of patients with hypertension, the overall outcomes for a group of patients with hypertension could be improved if compliance etc. were improved.[2I)
An important portion of the benefits that can be expected, can only be obtained if hypertension remains under control. The lack of this control accounts for a large number of deaths and disabilities which could really be avoided.
3. The Cost of Hypertension
As a consequence of the high prevalence and the associated fatal and nonfatal complications rate, hypertension implies a great economical and social cost. Because of this, hypertension is a leading target for the experts in health economy and costbenefit analysis.£22)
According to the US National Heart, Lung, and Blood Institute, hypertension cost $US 18.3 billion in the US in 1990. 69% of that cost was for direct health expenditure (hospital, physician, drug and nursing home charges) and 31 % for indirect costs in lost wages and lowered productivity.(23) In 1995, the estimated cost of hypertension was US$23.74 billion (US$17.07 billion in direct costs and $US6.67 billion in indirect costs).[24) However, these estimations are very conservative because
Dis Manage Health Outcomes 1997 Mar; 1 (3)
138
they are only based on hypertension treatment costs and exclude the costs of treating hypertensionrelated complications.
In the US, it has been possible to estimate that hypertension alone, increases the Medicare Costs by $US527 per elderly person per year, and that the combination of hypertension, smoking and hypercholesterolaemia increases that cost by $US1757J25]
In 1985 in Spain, it was estimated that the hypertension cost was $US830 million, which accounted for 3% of the national health expenditure in that year.[26] Direct costs represented 40% while indirect costs constituted 60% (table II). It was estimated that in 1985 hypertension was responsible for 50 000 years of potential life lost in the population aged <65 years. In a recent update, the total cost for 1994 was estimated as $US1660 million.l27]
Although comparisons of indirect costs are difficult because of calculation methodological complexities,[28] table I provides an overview of the significance of indirect costs of hypertension worldwide. It has been estimated that hypertension accounts for 19 100 disability-adjusted life years (DALYs) worldwide, i.e. 1.4% of the total DALYs.[13]
Inversely, direct costs are easy to estimate and consequently comparisons are more feasible (table III). There are important differences among countries, for example in Finland, Sweden and Spain, differences can be observed according to the intensity of the interventions.
Table II. Cost of hypertension in Spain (1985) [reproduced from Badia et al.[23,]
Concept
Primary healthcare
Hospital care
Pharmacy
Total direct cost
Attributable mortality
Attributable morbidity
Disability
Total indirect cost
Total cost
Cost (millions $US)"
219
78
110
407
317
8
194
519
926
a Amounts have been calculated taking an exchange rate of $US1 = 120 pesetas.
© Adis Internotionol Limited. All rights reserved.
Pardell et al.
Table III. Direct costs of hypertension in selected countries
Country Year Cost (millions Cost per person $US per year) ($US per year)
Finland 1972-77" 4.5 26.2 (North Karelia)
Sweden
Spain
1988
1985
153.0
489.0
18.3
12.7
a Population younger than 66 years.
Medication largely contributes to the increase in hypertension-related cost. Menard et al.[29] calculated that in France antihypertensive drugs expenditure has increased from F486.1 million in 1970 to F5063 million in 1990 (lO.4-fold increase), while in the same period, total medication expenditure only increased 1.94-fold.
All these estimates must be underestimates because the real cost of hypertension is much bigger in the real world. When considering the true cost, a major fraction of the cost of heart disease and stroke should be included, and these are actually huge.[29.30]
4. How to Reduce the Burden of Hypertension
It is very well known that important benefits can be expected if hypertension is adequately treated. It has been estimated in the US, that by reducing blood pressure in 3.6 million people with hypertension from a range of 100 to 104mm Hg to 95mm Hg or lower, about 12000 deaths could be prevented annually. This would represent a reduction of about $US 1 billion of the national health expendi ture.l3 I]
Although treating people with hypertension and doing it more intensively will result in an increase in direct costs, if the intervention is effective, it will curtail the indirect costs. As a result, the final balance in terms of avoiding social cost is very positive. (fig. 1). For this reason, and according to the last WHO Expert Committee Report,[2] early identification and effective management of individuals with hypertension should be promoted. In addition, the effective management of patients with hyper-
Dis Monage Health Outcomes 1997 Mar: 1 (3)
Hypertension: Epidemiology and Cost of Illness
tension should consider the new approaches mainly focused on the individualised regimesP21
Therefore, the main emphasis is centred on achieving the optimal control level in each community, as it was recommended in the World Conference on Hypertension Control. Education of healthcare professionals, patients and the general population is crucial for the success of the high blood pressure control programmes. Furthermore, secondary prevention approach is not fully satisfactory. Lenfant[331 recently stated that there is ample evidence that current approaches are less than optimal.
Despite the considerable efforts made to improve hypertension control, the incidence and prevalence of high blood pressure have not shown any tendency to decline over decades of follow-up of the Framingham cohort.l341 Hence, as it is stated in the last WHO Expert Committee Report, prevention of hypertension by measures aimed at reducing the blood pressure levels in the population as a whole should be considered as a fundamental component of a comprehensive strategy to prevent the hypertension-associated complications,l21
Since the association of hypertension with other cardiovascular risk factors increases the final risk, the implementation of integrated programmes will also entail the optimum community benefitsp51
Today, primary prevention of hypertension offers great opportunities with many successful experiences in different countries.[361 In fact, this is
Treated HT
Nontreated HT I
o Direct cost
o Indirect cost
I J Benefits . ~
I Fig. 1. Cost of treated and non·treated hypertension (HT). Ex· pected benefits from treatment.
© Adis International Limited. All rights reserved.
139
the only way to achieve the reduction of the burden, lowering the health cost by reducing the need and demand for medical services.l371
5. Conclusions
Hypertension is highly prevalent in most developed and developing countries and it accounts for more than 35% of total cardiovascular events. Although it is an easy condition to diagnose and treat, the hypertension control level in the community is really deficient.
The cost of hypertension is very high, accounting for around 3% of global health expenditure in some countries. Interventions aimed at reducing the incidence and prevalence of hypertension are needed. This is the only realistic approach to lowering the cost of the burden.
References I. Kaplan NM. Primary hypertension. From pathophysiology to
prevention. Arch Intern Med 1996; 156: 1919·20 2. Report of a WHO Expert Committee. Hypertension Control.
WHO Technical Report Series, 862. Geneva: World Health Organization, 1996
3. Report of a WHO Espert Committee. Arterial hypertension. WHO Technical Report Series, 628. Geneva: World Health Organization, 1978
4. Pardell H, editor. Arterial hypertension in Spain. 2nd ed. Ma· drid: Spanish League Against Arterial Hypertension (LELHA), 1986
5. WHO Regional Office for Europe. Study on hypertension con· trol monitoring at community level. Copenhagen: World Health Organization, 1994
6. Spanish Society of Hypertension - Spanish League Against Ar· terial Hypertension (SEH·LELHA). Control of arterial hyper· tension in Spain 1996. Madrid: Ministry of Health, 1996
7. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101·6
8. Kannel WB, McGee 0 , Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46·51
9. Kannel WB. Blood pressure as a cardiovascular risk factor. Pre· vention and treatment. JAMA 1996; 275: 1571·6
10. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765·74
11. Plans P, Pardell H, Salleras L. Epidemiology of cardiovascular disease risk factors in Catalonia, Spain. Eur J Epidemiol 1993; 9: 381·9
12. Stamler J, Stamler J, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risk: US population data. Arch Intern Med 1993; 153: 598·615
13. Murray CJL, Lopez AD. Evidence·based health policy: lessons from the Global Burden of Disease Study. Science 1996; 274: 740·3
Dis Manage Health Outcomes 1997 Mar: 1 (3)
140
14. Ruilope LM, editor. Present situation of hypertension detection, treatment and control in Spain. Madrid: Spanish League Against Arterial Hypertension (LELHA), 1995
15. Strasser T, Wilhelmsen L, editors. Assessing hypertension control and management. Copenhagen: WHO Regional Office for Europe, 1993
16. World Hypertension League. Hypertension control in our world: agenda for the coming decade. The 1995 WHL Ottawa Declaration. Final statement of the World Conference on Hypertension Control. 1995 June 22-24; Ottawa, Canada
17. Winickoff RN, Murphy PK. The persistent problem of poor blood pressure control. Arch Intern Med 1987; 147: 1393-6
18. Parde II H. Hypertension control, a pending challenge. Hypertension 1995; 12: 255-7
19. Report of a WHO Consultation. Workshop on hypertension control in the community: policy, strategies, monitoring and evaluation. 1994 Feb 27 - Mar I; Barcelona, Spain. Copenhagen: WHO Regional Office for Europe, 1995
20. Pardell H, Luque M, Aranda P, et al. Therapeutic compliance among hypertensives in Spain. Hypertension 1994; II: 92-6
21. Haynes RB, Gibson ES, Taylor W, et al. Process versus outcome in hypertension: a positive result. Circulation 1982; 65: 28-33
22. Johannesson M, Jonsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; I: 250-64
23. Thorn T. The economic costs of cardiovascular diseases in the United States, 1990. Bethesda (MD): National Heart, Lung, and Blood Institute, 1993
24. Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996; 156: 1926-35
25. Schauffer H, 0' Agostino R, Kannel WB. Risk forcardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 1993; 9: 146-54
26. Badia X, Rovira J, Tresserras R, et al. The cost of arterial hypertension in Spain. Med Clin (Barc) 1992; 99: 769-73
27. Pardell H, editor. Pharmacoeconomics of arterial hypertension. Madrid: Spanish Society of Hypertension - Spanish League Against Arterial Hypertension (SEH-LELHA), 1996
28. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-6
© Adis International Limited. All rights reserved.
Pardell et al.
29. Menard J, Cornu PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992, 6: 447 -58
30. Holloway RG, Witter Jr OM, Lawton KB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996; 46: 854-60
31. Perry Jr HM. Implication of clinical trials. Am J Med 1988, 85: 675-96
32. Pardell H, Armario P, Hernandez R. Progress in the 1980s and new directions in the 1990s with hypertension Management. Drugs 1992, 43: 1-5
33. Lenfant C. High blood pressure. Some answers, new questions and continuing challenges. JAM A 1996; 275: 1604-6
34. Dannenberg AL, Garrison RL, Kannel WB.lncidence of hypertension in the Framingham Study. Am J Public Health 1988; 78: 676-9
35. Pardell H, Tresserras R, Saito E, et al. Economic considerations for joint anti hypertension-antismoking programs. Can J Cardio11993, 9 Suppl. 0: 1750-1770
36. Pardell H, Armario P, Hernandez R, et al. Environmental factors, development of hypertension and opportunities for prevention. J Hypertens 1992; 9: 255-61
37. Fries JF, Koop CE, Beadle CE, et al. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 1993; 329: 321-5
About the Author: Dr Helios Pardell is currently Professor of Medicine at the University of Barcelona, Head of the Internal Medicine Department at the Red Cross Hospital in Hospitalet de L10bregat (Barcelona) and Executive Director of the CINDI Programme in Catalonia, Spain. His professional and research interests are mainly focused on epidemiology of hypertension and other cardiovascular risk factors and on intervention programmes at clinical and community levels. Correspondence and reprints: Dr H. Pardell, Department of Internal Medicine, Unit of Hypertension and Cardiovascular Risk, Red Cross Hospital, Av. Jose Molins, 29-41, 08906 Hospitalet de L1obregat, Barcelona, Spain.
Dis Manage Health Outcomes 1997 Mar; 1 (3)
Recommended